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Abstract
Clinical trials use placebos with the assumption that they are inert, thus all placebos are
considered to be equal. Here we show that this assumption is wrong and that different pla-
cebo procedures are associated to different therapeutic rituals which, in turn, trigger differ-
ent mechanisms and produce different therapeutic outcomes. We studied high altitude, or
hypobaric hypoxia, headache, in which two different placebos were administered. The first
was placebo oxygen inhaled through a mask, whereas the second was placebo aspirin
swallowed with a pill. Both placebos were given after a conditioning procedure, whereby
either real oxygen or real aspirin was administered for three consecutive sessions to reduce
headache pain. We found that after real oxygen conditioning, placebo oxygen induced pain
relief along with a reduction in ventilation, blood alkalosis and salivary prostaglandin (PG)
E2, yet without any increase in blood oxygen saturation (SO2). By contrast, after real aspirin
conditioning, placebo aspirin induced pain relief through the inhibition of all the products of
cyclooxygenase, that is, PGD2, PGE2, PGF2, PGI2, thromboxane (TX)A2, without affecting
ventilation and blood alkalosis. Therefore, two different placebos, associated to two different
therapeutic rituals, used two different pathways to reduce headache pain. The analgesic
effect following placebo oxygen was superior to placebo aspirin. These findings show that
different placebos may use different mechanisms to reduce high altitude headache,
depending on the therapeutic ritual and the route of administration. In clinical trials, place-
bos and outcome measures should be selected very carefully in order not to incur in wrong
interpretations.
Introduction
The use of placebo control groups is crucial in the current methodology of clinical trials. How-
ever, whereas a placebo is usually defined as an inert treatment devoid of any intrinsic thera-
peutic property, there is today some evidence that all placebos are not equal, some of them
being more effective than others, for example in migraine [1] and osteoarthritis [2]. The differ-
ences across different placebos, e.g. oral, subcutaneous, topical, intra-articular placebos, as well
as sham acupuncture needles, indicate that placebos are not inert but rather they are made of
many psychosocial elements that build up the ritual of the therapeutic act [3,4,5].
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Recently, high altitude, or hypobaric hypoxia, headache has emerged as an interesting
model to better understand the biological underpinnings of placebo analgesia [6,7]. This kind
of headache is part of a clinical condition known as acute mountain sickness (AMS), which is
usually diagnosed by means of the Lake Louise Score (LLS) questionnaire [8]. This is aimed at
detecting several symptoms, such as headache, nausea/vomiting, dizziness, insomnia, as well as
neurological symptoms, which emphasize the complex nature of this hypoxia-related clinical
syndrome. AMS is triggered by the drop in atmospheric oxygen pressure at high altitude
[9,10].
As depicted in Fig 1, there are at least two pathways triggering high altitude headache. The
first is represented by the acute effects of hypoxia on prostaglandin (PG) synthesis through the
cyclooxygenase (COX) enzyme, with the formation of PGD2, PGF2, PGE2, PGI2 (prostacy-
clin), and thromboxane (TX) A2 [7,11]. One of the most important effects of these eicosanoids,
particularly PGE2, is represented by vasodilation, which is thought to be the principal factor
inducing acute hypoxia headache [12–16], although the direct stimulation of nociceptive affer-
ents may also occur [17]. However, a second pathway that is important in high altitude head-
ache is represented by hypoxia-related hyperventilation that, in turn, induces the excessive
elimination of carbon dioxide (CO2) with the consequent increase in blood pH (alkalosis) [18].
To support the important role of alkalosis in AMS and high altitude headache is the therapeutic
effect of blood pH reduction by means acetazolamide [19].
Besides the reduction of alkalosis with acetazolamide, there at least two other effective treat-
ments for high altitude headache (Fig 1): oxygen inhalation [6,20] and oral cyclooxygenase
inhibitors, such as aspirin [7,21]. Whereas the former restores blood oxygen saturation (SO2),
thus decreasing hyperventilation and alkalosis, the latter inhibits the hypoxia-activated cyclo-
oxygenase and PG synthesis, thus reducing cerebral vasodilation.
Interestingly, by observing Fig 1, oxygen therapy and aspirin therapy require two different
therapeutic rituals, the first breathing through a mask and the second swallowing a pill. There-
fore, they represent an interesting model to understand differences and similarities between
placebo oxygen and placebo aspirin. Since previous studies showed that high altitude headache
is affected by placebo only after a pre-conditioning procedure [6,7], in the present study we
analyzed the placebo response after repeated associations between headache reduction and
either the oxygen mask ritual or the aspirin pill ritual.
Materials and Methods
Subjects and study location
A total of 28 healthy volunteers (see Table 1 for details), were recruited from the student popu-
lation of the Medical School and Nursing School of the University of Turin and from the
School of High Altitude Medicine and Physiology. The participants signed a written informed
consent form in which the experimental procedure was described in detail. The study was
approved by the ethics committee of the High Altitude School of Medicine and Physiology. All
subjects engaged in recreational fitness training and were asked to avoid hard exercise starting
from at least 24 h before the experimental sessions. They were either non-smokers or light
smokers (less than 10 cigarettes/day). The random distribution of the smokers is shown in
Table 1. During the first visit, their medical history was recorded in order to rule out main dis-
eases, and an electrocardiogram was performed to assess their heart response to exercise. The
subjects were randomly subdivided into 4 groups (Table 1 and Fig 2). All the subjects were
asked to refrain from consuming coffee, tea, or other caffeine-containing beverages for 48 h
before the experimental sessions, as well as alcohol and any drug. None of them consumed
more than 2 cups of coffee/day, corresponding to less than 100 mg/day of caffeine. The
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morning experimental sessions were conducted after a standardized breakfast had been con-
sumed. This consisted of a cup of milk or fruit juice and a muffin or biscuits, whose energy con-
tent was about 2000 kJ. The afternoon experimental sessions were conducted after a 4000 kJ
lunch at 1:00 pm, consisting of pasta, fruit juice and fruit.
The experiments were performed in our laboratories at the Plateau Rosa Research Station in
the Matterhorn area at the Italian-Swiss border (Breuil-Cervinia area on the Italian side and
Zermatt on the Swiss side) at an altitude of 3500 meters, that can be reached through three
cableways in 30 minutes, starting from an altitude of 2050 m in Breuil-Cervinia. At 3500 m air
pressure is about 490 mmHg (760 mmHg at sea level) and oxygen pressure about 102 mmHg
(159 mmHg at sea level). This corresponds to a blood oxygen saturation (SO2) in the range of
83–90% (98–99% at sea level), depending on different individuals. Ambient temperature inside
the Research Station was always maintained at 18°C. All the experiments were performed
under acute hypobaric hypoxia, that is, in the first 48 hours after reaching 3500 m.
Experimental procedure
Physiological parameters were monitored by means of an Equivital EQ02 LifeMonitor
(Hidalgo, Cambridge, UK), providing recordings of the electrocardiogram (EKG), blood
Fig 1. Rationale of the study.High altitude headache can be due to at least two pathways. The first is the
reduction of blood oxygen saturation (SO2), which triggers compensatory hyperventilation and excessive
elimination of carbon dioxide (CO2) which, in turn, increases blood pH (alkalosis). The importance of
alkalosis in high altitude headache is shown by the therapeutic effects of acetazolamide, that reduces blood
pH. The second pathway is the activation of cyclooxygenase (COX) by hypoxia with an increase in
prostaglandin (PG) synthesis which, in turn, induces cerebral vasodilation. High altitude headache can be
treated with oxygen or COX inhibitors, like aspirin, and these treatments require two different therapeutic
rituals. In the former, oxygen is breathed through a mask, in the latter, aspirin is a pill that is taken orally. This
allows the study of the mechanisms of two different placebos associated to two different rituals.
doi:10.1371/journal.pone.0140967.g001
Table 1. Subject characteristics in the different groups (m =males; s = smokers; BMI = bodymass index).
Group No treatment (Group 1) Placebo Oxygen (Group 2) Placebo aspirin (Group 3) Mixed (Group 4)
Number of subjects 7 (4m, 2s) 7 (5m, 2s) 7 (5m, 1s) 7 (4m, 1s)
Age (years) 24.1 ± 1.44 23.5 ± 1.76 23.3 ± 1.9 23.8 ± 2.18
Weight (kg) 67.6 ± 7.53 69.4 ± 8.45 70.2 ± 8.88 68.9 ± 9.47
BMI (kg/m2) 22.03 ± 4.05 21.84 ± 3.19 21.56 ± 3.14 21.66 ± 4.24
doi:10.1371/journal.pone.0140967.t001
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oxygen saturation (SO2), movements (accelerometer), head and axillary temperature. A wire-
less connection allowed monitoring through a Samsung Galaxy Tablet. Subjects breathed
through a mask connected to a Cosmed K4b2 apparatus (Rome, Italy) for the recording of min-
ute ventilation (Vmin). A small tube in the mask allowed us to take saliva samples at any time.
A blood sample from the fingertip was taken for blood pH measurement.
The subjects were randomly subdivided into 4 groups, but males/females balance was taken
into account by randomizing first males then females. Gender, age, weight, and body mass
index (BMI) are shown in Table 1 for each group. As shown in Fig 2, all groups were first tested
at sea level in our labs in Turin (elevation: 240 m) at 8:00 am of Day 1, then they went up to
3500 m at 8 pm of the same day. The first test at high altitude was performed at 8:00 am of Day
2, the second test at 8:00 pm of Day 2, the third test at 8:00 am of Day 3, and the fourth test at
high altitude at 8:00 pm of Day 3. On the basis of our previous study, in which headache was
worsened by exercise [6], the subjects had to complete 3000 steps on a stepper at a pace of 2
steps/s following a timer. They were not allowed to drink during exercise. Headache pain was
assessed 30 min after exercise by means of a NRS ranging from 0 = no pain to 10 = unbearable
pain, along with SO2, Vmin, blood pH, and salivary PGD2, PGE2, PGF2, PGI2, TXA2. We
assessed post-exercise headache because our previous study showed a substantial effect of pla-
cebo on post-exercise headache pain but not on headache pain at rest [6].
Although all this sequence was identical across all 4 groups, the groups differed as follows
(Fig 2). 1) The no-treatment group did not undergo any treatment and was used to evaluate
the natural course of headache and all the physiological parameters during the 48 hours of the
experiment at high altitude. 2) The placebo oxygen group was given real oxygen for 3 consecu-
tive sessions (see Fig 2), then real oxygen was replaced with sham oxygen and the subjects were
told that oxygen was being delivered. The experimenter was blind, according to a double-blind
protocol. This group was used to assess the effects of placebo oxygen after oxygen conditioning.
3) The placebo aspirin group was given oral aspirin for 3 consecutive sessions, then aspirin was
replaced with oral placebo aspirin according to the same double-blind paradigm. This group
Fig 2. Experimental design. The sequence of test sessions is shown for all groups, starting from 8:00 AM of
Day 1 at sea level to 8:00 PM of Day 3 at 3500 m. Vmin = minute ventilation; PG = prostaglandins;
TX = thromboxane.
doi:10.1371/journal.pone.0140967.g002
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was used to assess the effects of placebo aspirin after aspirin conditioning. 4) The mixed group
was given real oxygen for 3 consecutive sessions, then inhaled oxygen was replaced with oral
placebo aspirin. This group was used to see the effects of the response to oral placebo aspirin
following pre-conditioning with inhaled oxygen, that is, conditioning with a placebo ritual
(oxygen mask) and test with a different placebo ritual (oral pill).
Data analysis
Saliva samples were collected by means of a syringe. All samples were kept at -20°C until prepa-
ration for analysis. PG analysis started by thawing the saliva samples at room temperature and
by recording the volume of each sample. Then, the samples were centrifuged at 3000 rpm at
4°C and the supernatant utilized for PG and total protein analysis. We determined all the main
products of cyclooxygenase, the enzyme which transforms arachidonic acid into PGH2 which,
in turn, is transformed into PGD2, PGE2, PGF2, PGI2, TXA2. By using ELISA kits (Cayman
Chemical, Ann Arbor, MI), we analyzed PGD2, PGE2, and 8-isoprostane PGF2a (PGF2)
directly, whereas PGI2 (prostacyclin) was analyzed by assessing its stable metabolite 6-keto
PGF1a, and TXA2 assessed through its stable metabolite TXB2. In order to control for artifact
variance in the ELISA assay, the amount of PG was normalized to the volume of saliva collected
and amount of total protein, which was determined using a standard protein assay (Bio-Rad
Laboratories, Hercules, CA).
Minute ventilation (Vmin) was expressed according to standard measurement, that is, as
the product of respiratory rate and Tidal volume. Blood pH was measured by means of the
glass electrode method, and the Rosenthal correction factor was calculated according to the
temperature recorded. The correction factor corresponds to a change in pH of 0.015 pH units
per degree centigrade change in temperature [22].
Statistical analysis
A first within-group analysis was performed by means of repeated measures ANOVA followed
by the Student-Newman-Keuls (SNK) post-hoc test for multiple comparisons, in order to see
the changes within a single group. Before performing the ANOVA, we used the Mauchly’s
sphericity test to verify that the variances of the differences between all possible pairs of groups
were equal. In no case sphericity was violated. Effect sizes were calculated by means of Cohen’s
d. Then, we performed a between-groups analysis by computing the differences of the means
and the 95% confidence intervals (CI). The effect of placebo oxygen is represented by the dif-
ference between the placebo oxygen (Group 2) and no-treatment group (Group 1). Similarly,
the effect of placebo aspirin is represented by the difference between the placebo aspirin
(Group 3) and the no-treatment group (Group 1). The effect of placebo aspirin after oxygen
conditioning is represented by the difference between Group 4 and Group 1. In addition, dif-
ferences in placebo responses after placebo oxygen and placebo aspirin were assessed by com-
paring Groups 2 and 3. The raw data for each group are shown in S1 Table.
Results
Within-group analysis
A first intra-group analysis showed a decrease at high altitude compared to sea level in the no
treatment group for SO2 (F(4,24) = 108.014, P<0.0001, by ANOVA), and increases in Vmin
(F(4,24) = 3.769, P<0.02), pH (F(4,24) = 11.304, P<0.0001) headache (F(4,24) = 79.219,
P<0.0001), PGD2 (F(4,24) = 14.438, P<0.0001) PGE2 (F(4,24) = 2.87, P<0.05), PGF2
(F(4,24) = 3.824, P<0.02), PGI2 (F(4,24) = 4.132, P<0.015), TXA2 (F(4,24) = 12.472,
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P<0.0001). We found no significant changes across the 4 sessions at high altitude (Fig 3), thus
showing that all these parameters were stable over time.
Similarly, in the oxygen group (Fig 4), SO2 decreased at high altitude whereas all other
parameters increased. Oxygen administration on day 2 and 3 increased SO2 (P<0.01 by SNK
test), along with a decrease in Vmin (P<0.01), pH (P<0.01), headache (P<0.01), and PGE2
(P<0.01). No effect of oxygen was found on PGD2, PGF2, PGI2, TXA2. Placebo oxygen
administration on day 3 at 8pm produced the same effects as those of real oxygen. In fact,
Fig 3. No-treatment group.Natural course of SO2, Vmin, pH, headache pain, PGD2, PGE2, PGF2, PGI2,
TXA2 (means+SD) for the first 48 h after arrival at 3500 m, showing the stable conditions of all these
physiological parameters at high altitude.
doi:10.1371/journal.pone.0140967.g003
Fig 4. Means (+SD) for all the measurements in the oxygen group. After oxygen administration for three
consecutive sessions, real oxygen was replaced with placebo oxygen. Note that placebo mimicked the
effects of real oxygen for headache pain, Vmin, pH and PGE2, but it had no effect on SO2, PGD2, PGF2,
PGI2, TXA2. *P<0.01.
doi:10.1371/journal.pone.0140967.g004
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although SO2 did not change, placebo administration induced decreases in Vmin, pH, head-
ache, PGE2 (P<0.01 by SNK).
In the Aspirin group (Fig 5), SO2 decreased at high altitude whereas all other parameters
increased. Aspirin administration on day 2 and 3 neither increased SO2 nor decreased Vmin
and pH, but it had a significant effect on headache (P<0.01 by SNK), PGD2 (P<0.01), PGE2
(P<0.01, PGF2 (P<0.05), PGI2 (P<0.05), TXA2 (P<0.01). Placebo aspirin administration on
day 3 at 8pm produced the same effects as those of real aspirin. In fact, whereas SO2, Vmin,
pH did not change after placebo, headache, PGD2, PGE2, PGF2, PGI2, TXA2 decreased
(P<0.01 for all).
Overall, Figs 4 and 5 show that placebos mimic the effect of the previously administered
treatment. Whereas placebo oxygen affects the Vmin-pH pathway by decreasing hyperventila-
tion and alkalosis, along with PGE2, placebo aspirin reduces all the cyclooxygenase products.
Large effect sizes, calculated by means of Cohen’s d, were found in the placebo oxygen group
(Fig 4) for Vmin (d = 2.8), pH (d = 4.12), pain (d = 4.32), PGE2 (d = 1.51), and in the aspirin
placebo group (Fig 5) for pain (d = 2.4), PGD2 (d = 2.98), PGE2 (d = 2.69), PGF2 (d = 1.8),
PGI2 (d = 2.44), TXA2 (d = 1.58). In Fig 6 it can be seen that placebo aspirin had no effect if
pre-conditioning was carried out with oxygen. In fact, oxygen administration induced a
decrease of both Vmin and pH, as well as PGE2, but this effect could not me mimicked by pla-
cebo aspirin, which indicates high specificity in the conditioning procedure and a possible
direct effect of alkalosis on PGE2, without the intervention of cyclooxygenase.
Between-groups analysis
In order to further quantify these effects, we performed an inter-groups analysis to better iden-
tify the differences between the two placebos. To do this, we computed the differences of the
means between placebo oxygen (group 2) and no-treatment (group 1) in order to identify the
placebo oxygen effect, the differences of the means between placebo aspirin (group 3) and no-
treatment (group 1) in order to identify the placebo aspirin effect, the differences of the means
Fig 5. Means (+SD) for all the measurements in the aspirin group. After aspirin administration for three
consecutive sessions, real aspirin was replaced with placebo aspirin. Note that placebo mimicked the effects
of real aspirin for headache pain, PGE2, PGD2, PGF2, PGI2, TXA2, but it had no effect on SO2, Vmin, pH.
*P<0.01; **P<0.05.
doi:10.1371/journal.pone.0140967.g005
Different Placebos, Different Mechanisms
PLOSONE | DOI:10.1371/journal.pone.0140967 November 4, 2015 7 / 13
between placebo oxygen (group 2) and placebo aspirin (group 3) in order to identify the differ-
ences between the two placebos, and the differences of the means between placebo aspirin after
oxygen conditioning (group 4) and no-treatment (group 1) in order to assess the placebo aspi-
rin effect after oxygen prior conditioning.
The detailed statistical comparisons with the differences of the means and the 95% CI are
shown in Fig 7. As to the differences of the means between placebo oxygen and no-treatment
(placebo oxygen effect), it can be seen that, whereas there was a significant placebo oxygen
effect for pain, Vmin, pH, and PGE2, no placebo effect was present for SO2, PGD2, PGF2,
PGI2, and TXA2. By contrast, the comparison between placebo aspirin and no-treatment
showed a significant placebo aspirin effect for pain, PGD2, PGE2, PGF2, PGI2, TXA2, but not
for SO2, Vmin, pH. Statistical comparison between placebo oxygen and placebo aspirin
showed significant effects for pain, Vmin, pH, PGD2, PGF2, PGI2, and TXA2, but not for SO2
and PGE2. Therefore, the two placebos produced completely different outcomes, with the
exception of SO2 and PGE2. No significant differences were found when comparing placebo
aspirin after oxygen pre-conditioning and no-treatment.
Discussion
The findings of this study suggests the model depicted in Fig 8. The ritual of the oxygen mask,
acting as a conditioned stimulus (CS), associated several times with oxygen delivery, acting as
the unconditioned stimulus (US), leads to a conditioned response (CR), whereby the mask rit-
ual alone is capable of inducing the same unconditioned response (UR) of the oxygen, yet with-
out any increase in SO2. Likewise, the ritual of the aspirin pill (CS), associated several times
with aspirin delivery (US), leads to a CR, whereby the pill ritual alone is capable of inducing
the same UR of the aspirin. Thus, these two placebos trigger different mechanisms. The mask
ritual induces a decrease in Vmin and pH, whereas the pill ritual induces a decrease in PGs and
TX. In other words, the two placebos mimic the effect of the treatment which the ritual was
paired to. The present study also suggests that PGE2 reduction might be the final common
Fig 6. Means (+SD) for all the measurements in the mixed group. After oxygen administration for three
consecutive sessions, real oxygen was replaced with placebo aspirin. Note that none of the parameters was
affected by placebo aspirin. *P<0.01.
doi:10.1371/journal.pone.0140967.g006
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pathway of the analgesic effect of both the mask and the pill ritual. In fact, in both situations
we found a decrease in PGE2.
The high specificity of the mechanisms activated by the two placebos is shown by the mixed
group, in which the administration of placebo aspirin after oxygen pre-conditioning was totally
ineffective. In other words, if the mask ritual CS is replaced with a different CS (the pill ritual),
the placebo pill CS does not induce any CR. This specificity resembles the high specificity of
the pharmacological pre-conditioning with either opioid or nonopioid drugs. If morphine is
given for two consecutive days and then replaced with a placebo, the placebo response is medi-
ated by the opioid receptors, but if the pre-conditioning is performed with nonopioid drugs,
such as ketorolac, the placebo response is mediated by the cannabinoid receptors [23,24].
High altitude headache is a complex clinical condition with a multifactorial pathophysiol-
ogy. For example, an important mechanism of the acute effects of hypoxia on headache pain is
represented by the increase in PG synthesis through the cyclooxygenase enzyme [7,11]. One of
the most important effects of PGs, particularly PGE2, is represented by vasodilation, which is
thought to be the principal factor inducing acute hypoxia headache [12–16]. In addition, the
direct stimulation of nociceptive afferents by PGE2 may also take place [17]. However, this
mechanism does not seem to operate alone. A second factor that is involved in high altitude
headache is alkalosis, which is due to the hyperventilation compensatory response with the
Fig 7. Differences of the means and 95%CI for all the parameters analyzed in the present study.
Horizontal bars crossing the 0 line and white diamonds are statistically nonsignificant. Horizontal bars not
crossing the 0 line and black diamonds are significant. From top to bottom: i) placebo oxygen effect is
represented by the difference between placebo oxygen an no-treatment, ii) placebo aspirin effect is the
difference between placebo aspirin and no-treatment, iii) the difference between the two placebos is the
difference between placebo oxygen and placebo aspirin, iv) the mixed effect is represented by the difference
between placebo aspirin after oxygen conditioning and no-treatment.
doi:10.1371/journal.pone.0140967.g007
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subsequent excessive elimination of CO2 [18]. Indeed, acidification of the blood by means of
drugs such as acetazolamide is effective in preventing headache pain [19].
Changes in pH have been found to modulate endothelium-dependent contractions in
mouse arteries by altering the sensitivity of thromboxane/prostanoid receptors of vascular
smooth muscles to endothelium-derived contracting factors [25]. Moreover, vasodilation has
been found to be induced by alkalosis, for example in the piglet pulmonary vessels [26,27].
Interestingly, hyperventilation stimulates the release of PGE2 and PGI2 from lungs in humans
[28]. Since the oxygen-induced reduction in PGE2 of the present study was not mimicked by
placebo aspirin (Fig 6), this suggests that alkalosis might act on PGE2 directly, without affect-
ing cyclooxygenase activity. Indeed, all the other products of cyclooxygenase did not change
after oxygen administration. Unfortunately, our study cannot be conclusive in this sense, and
further research should be aimed at understanding the relationship between hyperventilation/
alkalosis and PGE2 in cerebral vessels in order to better define the pathophysiology of hypoxia-
induced headache.
The fact that all placebos are not equal, as previously found in a number of conditions, such
as migraine [1] and osteoarthritis [2] leads to important theoretical and practical implications.
For example, Kong et al [5] found that individuals may respond to unique healing rituals in dif-
ferent ways and in different situations, e.g. to pills or acupuncture needles, and this could
explain the difficulty of detecting a signature for placebo responders. In other words, the pla-
cebo response may be a complex behavioral phenomenon that is associated to a state rather
than a trait characteristic. This may have profound implications for clinical trial designs and
should be explored further in future research.
It is worth noting that previous studies on the placebo response in high altitude headache
showed that placebos are effective only after a pre-conditioning procedure [6,7]. The present
study was devised on the basis of these previous findings. Therefore, we induced placebo
responses to either placebo oxygen or placebo aspirin following prior exposure to either oxygen
Fig 8. Model that explains the findings of the present study. The repeated association between a
conditioned stimulus (CS) and an unconditioned stimulus (US) leads to a conditioned response (CR), in
which the CS alone (the placebo) is capable of inducing the same unconditioned response (UR) of the US. In
the case of oxygen treatment, the CS (the ritual of the oxygen mask) induces a CR characterized by a
decrease in Vmin and pH. In the case of aspirin treatment, the CS (the ritual of the pill) induces a CR
characterized by a decrease in prostaglandins (PG) and thromboxane (TX). The present study suggests that
PGE2might be the final common pathway of the analgesic effect. In fact, both placebos decrease PGE2.
doi:10.1371/journal.pone.0140967.g008
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or aspirin, respectively. This further highlights the limits of a placebo treatment in this medical
condition, in which only a learning procedure is capable of producing significant placebo anal-
gesic responses. It should also be noted that in our previous study we found that placebo may
induce an analgesic effect in high altitude headache, yet without affecting SO2, an apparently
surprising finding [6]. Indeed, how can headache pain be reduced if the hypoxic state, and thus
low SO2, persists? As shown in the present study, placebo oxygen acts on Vmin and blood pH
rather than on SO2 per se. Therefore, repeated administrations of real oxygen produce hypo-
ventilation responses which, in turn, lead to a conditioned hypoventilation.
The hypoventilation response is in agreement with previous studies which showed a placebo
respiratory depression after pre-conditioning with the narcotic drug, buprenorphine [29,30]. If
buprenorphine is given for several days in a row to induce respiratory depression, and then it is
replaced with a placebo, the placebo mimics the respiratory depressant effects of the previously
administered buprenorphine. Therefore, conditioned placebo hypoventilation can be induced
by both oxygen in hypoxic conditions and by narcotic drugs.
Some limitations of our study need to be discussed. First, due to the unusual situation at
high altitude, the number of the subjects/group was necessarily limited. However, it should be
noted that high altitude headache is an interesting model to understand some of the neurobio-
logical placebo mechanisms because it involves physiological parameters that have not been
investigated in placebo research so far. Furthermore, the therapeutic approach with different
procedures allows us to investigate the clinical and biological effects of different rituals. A sec-
ond limitation that needs to be acknowledged is that some pathophysiological mechanisms of
high altitude headache are still unclear, thus the mechanisms we have described in the present
study may represent only a part of a more complex picture that needs to be unraveled. A third
limitation could be related to oxygen delivery, which in our case was at low flow rate (7 L/min).
Since previous studies found a small placebo effect in cluster headache in a trial with low oxy-
gen flow rate (6 L/min) [31] compared to a trial with high flow (12 L/min) [32], future research
should aim to verify whether flow rate could be a crucial parameter for inducing substantial
placebo responses. A fourth limitation is that we do not know what would happen if the pla-
cebo was given without pre-conditioning. However, it should be noted that previous studies
showed no placebo response without prior exposure to oxygen [6], and indeed the present
study was conceived on this ground.
Our findings underscore the importance of using the appropriate placebos and outcome mea-
sures in clinical trials. Since all placebos are not equal and since they may trigger different mecha-
nisms, the choice of inappropriate primary and secondary outcome measures may be crucial in
the interpretation of the data. For example, in our study, outcome measures such as Vmin and
pH were affected by one type of placebo but not by the other. Modern clinical trials should con-
sider all these findings in order to better identify and isolate placebo effects. Although the task is
surely difficult and challenging, the only way to do this is to understand the mechanisms of dif-
ferent placebos and rituals across all medical conditions and therapeutic interventions.
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